Summit Global Investments Alkermes Plc. Transaction History
Summit Global Investments
- $1.48 Billion
- Q2 2024
A detailed history of Summit Global Investments transactions in Alkermes Plc. stock. As of the latest transaction made, Summit Global Investments holds 46,808 shares of ALKS stock, worth $1.29 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
46,808
Previous 39,895
17.33%
Holding current value
$1.29 Million
Previous $1.08 Million
4.44%
% of portfolio
0.08%
Previous 0.08%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
346Shares Held
183MCall Options Held
209KPut Options Held
89.4K-
Black Rock Inc. New York, NY29.1MShares$801 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20MShares$551 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.4MShares$395 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$303 Million0.03% of portfolio
-
State Street Corp Boston, MA9.22MShares$254 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.52B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...